全文获取类型
收费全文 | 4517篇 |
免费 | 359篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 56篇 |
儿科学 | 105篇 |
妇产科学 | 70篇 |
基础医学 | 856篇 |
口腔科学 | 146篇 |
临床医学 | 445篇 |
内科学 | 791篇 |
皮肤病学 | 142篇 |
神经病学 | 634篇 |
特种医学 | 156篇 |
外科学 | 437篇 |
综合类 | 16篇 |
一般理论 | 3篇 |
预防医学 | 286篇 |
眼科学 | 93篇 |
药学 | 333篇 |
中国医学 | 9篇 |
肿瘤学 | 316篇 |
出版年
2024年 | 5篇 |
2023年 | 39篇 |
2022年 | 64篇 |
2021年 | 141篇 |
2020年 | 83篇 |
2019年 | 112篇 |
2018年 | 109篇 |
2017年 | 118篇 |
2016年 | 151篇 |
2015年 | 185篇 |
2014年 | 217篇 |
2013年 | 235篇 |
2012年 | 406篇 |
2011年 | 359篇 |
2010年 | 231篇 |
2009年 | 205篇 |
2008年 | 303篇 |
2007年 | 318篇 |
2006年 | 338篇 |
2005年 | 254篇 |
2004年 | 246篇 |
2003年 | 189篇 |
2002年 | 164篇 |
2001年 | 53篇 |
2000年 | 42篇 |
1999年 | 50篇 |
1998年 | 44篇 |
1997年 | 29篇 |
1996年 | 17篇 |
1995年 | 12篇 |
1994年 | 8篇 |
1993年 | 10篇 |
1992年 | 16篇 |
1991年 | 8篇 |
1990年 | 7篇 |
1989年 | 8篇 |
1988年 | 8篇 |
1987年 | 9篇 |
1986年 | 10篇 |
1985年 | 13篇 |
1984年 | 16篇 |
1983年 | 5篇 |
1982年 | 6篇 |
1981年 | 3篇 |
1971年 | 2篇 |
1970年 | 4篇 |
1967年 | 3篇 |
1954年 | 6篇 |
1932年 | 5篇 |
1931年 | 2篇 |
排序方式: 共有4894条查询结果,搜索用时 15 毫秒
991.
992.
993.
Here we demonstrate a synergistic and tumor selective cytotoxic effect by combined treatment with naphthoxylosides, polyamine synthesis inhibitor, and polyamine based nitric oxide (NO) donor, using in vitro human tumor models. We have earlier reported that heparan sulfate priming naphthoxyloside, 2-(6-hydroxynaphthyl)-O-beta-D-xylopyranoside, which inhibits growth of human tumor cells in vitro and in vivo models, undergoes NO dependent cleavage and accumulates in the nuclei of tumor cells. Polyamine depletion using alpha-difluoromethylornithine (DFMO) increases both the number of NO sensitive sites in heparan sulfate and uptake of the polyamine based NO donor, spermineNONOate, thereby enhancing formation of growth-inhibitory NO induced heparan sulfate products with specific cytotoxic effect on tumor cells. We also show that peracetylation of xylosides doubles the antiproliferative effect towards human cancer cells by making these compounds more permeable to the cells. 相似文献
994.
Loibl S Murmann C Schwedler K Warm M Müller L Heinrich G Nekljudova V von Minckwitz G 《Cancer chemotherapy and pharmacology》2009,63(5):953-958
Purpose The aim of the RiTa trial is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule in anthracycline
pre-treated metastatic breast cancer patients.
Methods Starting dose of bendamustine was 50 mg/m2 and was stepwise increased by 10 mg/m2 up to 70 mg/m2. The starting dose of paclitaxel
was 60 mg/m2 and was increased up to 90 mg/m2. There are five pre-defined dose levels with three patients per dose level (maximum
six patients) and six patients in the last dose level according to the Goodman design. Dose-limiting toxicities were defined
as severe neutropenia and thrombocytopenia as well as non-haematological toxicities ≥NCI-CTC grade 3 in the first cycle.
Results No dose-limiting toxicity up to 70 mg/m2 bendamustine and 90 mg/m2 paclitaxel occurred during the first cycle. Over all cycles, the following severe haematological toxicities (grade 3 and
4) were documented: neutropenia five patients and anaemia one patient. Relevant grade 3 and 4 non-haematological toxicities
over all cycles were fatigue two patients, dyspnoea one patient, infection four patients and bone pain in one patient. Five
serious adverse events, but no therapy related death occurred. Five patients showed a complete or partial remission, six patients
stable disease and six progressed during treatment. The median progression-free survival was 8 months.
Conclusion Treatment with weekly bendamustine and paclitaxel is a feasible and effective regimen in patients with metastatic breast cancer.
The recommended dose for forthcoming phase II study is 70 mg/m2 bendamustine and 90 mg/m2 paclitaxel.
In part presented at the congress of the German Cancer Society on February 2008 in Berlin. 相似文献
995.
Welch JE Bengtson P Svensson K Wittrup A Jenniskens GJ Ten Dam GB Van Kuppevelt TH Belting M 《International journal of oncology》2008,32(4):749-756
The growth-promoting polyamines are polybasic compounds that efficiently enter cancer cells by as yet incompletely defined mechanisms. Strategies to inhibit their internalization may have important implications in the management of tumor disease. Here, we show that cellular binding and uptake of polyamines are inhibited by a single chain variable fragment anti-heparan sulfate (HS) antibody. Polyamine uptake was inhibited in a dose-dependent manner, and was associated with compensatory up-regulation of ornithine decarboxylase (ODC), i.e. the key enzyme of the polyamine biosynthesis pathway. Conversely, depletion of intracellular polyamines by the specific ODC-inhibitor alpha-difluoromethylornithine (DFMO) resulted in increased cellular binding of polyamine and anti-HS antibody. Importantly, anti-HS antibody also efficiently targeted DFMO-induced polyamine uptake, and combined polyamine biosynthesis inhibition by DFMO, and uptake inhibition by anti-HS antibody attenuated tumor cell proliferation in vitro. In conclusion, cell-surface HS proteoglycan is a relevant target for antibody-mediated inhibition of the uptake of polyamines, and polyamine-dependent cell proliferation. 相似文献
996.
Kapischke M Fischer T Tiessen K Tschesche H Bruch HP Kalthoff H Kruse ML 《International journal of oncology》2008,32(1):273-282
Matrix metalloproteinases (MMPs) play a central role in tissue maintenance, inflammation and during tumour invasion and metastasis. The impact of MMPs in cancer has encouraged the development of novel MMP-inhibitors without adverse effects on the cell viability. We describe here the synthesis and characterisation of a triazine-derivative as a highly potent MMP-inhibitor. The new compound Triazin 17-2 was developed on the basis of a triazine backbone as a well known and well tolerated chemical scaffold. It was de novo synthesized and tested for MMP inhibition in a cell free assay. In vitro characterisation included tests for cell viability, protein expression and MMP activity in PancTu-1 cells. Effectivity of MMP inhibition was analysed in vitro by invasion assay. Triazin 17-2 was investigated in vivo using an orthotopic pancreatic ductal adenocarcinoma (PDAC) xenograft model in SCID/bg mice. Triazin 17-2 proved to have no adverse effects on cell viability in vitro at concentrations effectively inhibiting MMPs in an invasion assay. Application of Triazin 17-2 in vivo in the orthotopic PDAC model in SCID/bg mice showed a significant reduction of primary tumour weight using conservative therapy and inhibition of metastasis in adjuvant therapy. The MMP-inhibitor Triazin 17-2 was developed and characterised in vitro and in vivo. The new compound has no intrinsic activity to kill cells but is very effective in inhibition of MMPs. In vivo testing revealed that MMP-inhibitors are useful tools in anticancer therapy reducing tumour size and invasion even without direct effects on cell survival. 相似文献
997.
Gockel I Moehler M Frerichs K Drescher D Trinh TT Duenschede F Borschitz T Schimanski K Biesterfeld S Herzer K Galle PR Lang H Junginger T Schimanski CC 《Oncology reports》2008,20(4):845-850
This study aimed to define the co-expression pattern of target receptor tyrosine kinases (RTKs) in human esophageal adenocarcinoma and squamous cell cancer. The co-expression pattern of vascular endothelial growth factor receptor (VEGFR)1-3, platelet-derived growth factor receptor (PDGFR)alpha/beta and epidermal growth factor receptor 1 (EGFR1) was analyzed by RT-PCR in 50 human esophageal cancers (35 adenocarcinomas and 15 squamous cell cancers). In addition, IHC staining was applied for the confirmation of the expression and analysis of RTK localisation. The adenocarcinoma samples revealed VEGFR1 (97%), VEGFR2 (94%), VEGFR3 (77%), PDGFRalpha (91%), PDGFRbeta (85%) and EGFR1 (97%) expression at different intensities. Ninety-four percent of the esophageal adenocarcinomas expressed at least four out of six RTKs. Similarly, squamous cell cancers revealed VEGFR1 (100%), VEGFR2 (100%), VEGFR3 (53%), PDGFRalpha (100%), PDGFRbeta (87%) and EGFR1 (100%) expression at different intensities. All esophageal squamous cell carcinomas expressed at least four out of six RTKs. While VEGFR1-3 and PDGFRalpha and EGFR1 was expressed by tumor cells, PDGFRbeta was restricted to stromal cells, which also depicted a PDGFRalpha expression. Our results revealed a high rate of RTK co-expression in esophageal adenocarcinoma and squamous cell cancer and may encourage application of multi-target RTK inhibitors within a multimodal concept as a promising novel approach for innovative treatment strategies. 相似文献
998.
Sasahira T Kirita T Oue N Bhawal UK Yamamoto K Fujii K Ohmori H Luo Y Yasui W Bosserhoff AK Kuniyasu H 《Cancer science》2008,99(9):1806-1812
Melanoma inhibitory activity (MIA) is an 11-kDa secretory protein isolated from malignant melanoma cells that is correlated with invasion and metastasis in various human malignancies. We examined MIA expression in 62 oral squamous cell carcinomas (OSCC) by immunohistochemistry. MIA expression was significantly associated with nodal metastasis ( P = 0.00018). MIA expression was also associated with expression of high mobility group box-1 (HMGB1) ( P < 0.0001) and lymph vessel density ( P < 0.0001). Expression levels of MIA, HMGB1, nuclear factor kB (NFkB) p65 and HMGB1–NFkB p65 binding were significantly higher in a metastatic human OSCC cell line (HSC3) than those in a non-metastatic OSCC cell line (HSC4). Treatment with receptor for advanced glycation end products (RAGE) antisense or small interfering RNA and human recombinant HMGB1 (hrHMGB1) did not affect MIA expression, whereas HMGB1 antisense or siRNA treatment decreased MIA expression in HSC3 cells. Then HMGB1 enhanced MIA expression as an NFkB cofactor but not as a RAGE ligand. MIA neutralization by MIA antibodies increased extracellular signal-related kinase 1/2 phosphorylation, but decreased p38 phosphorylation and the expression of vascular epithelial growth factor (VEGF)-C and -D. Treatment with p38 inihibitor decreased VEGF-C and -D expression in HSC3 cells. These results suggest that MIA expression is enhanced by the interaction of intracellular HMGB1 and NFkBp65 and MIA is closely involved in tumor progression and nodal metastasis by the increments of VEGF-C and VEGF-D in OSCC. ( Cancer Sci 2008; 99: 1806– 1812) 相似文献
999.
Müller-Hermelink N Braumüller H Pichler B Wieder T Mailhammer R Schaak K Ghoreschi K Yazdi A Haubner R Sander CA Mocikat R Schwaiger M Förster I Huss R Weber WA Kneilling M Röcken M 《Cancer cell》2008,13(6):507-518
Immune responses may arrest tumor growth by inducing tumor dormancy. The mechanisms leading to either tumor dormancy or promotion of multistage carcinogenesis by adaptive immunity are poorly characterized. Analyzing T antigen (Tag)-induced multistage carcinogenesis in pancreatic islets, we show that Tag-specific CD4+ T cells home selectively into the tumor microenvironment around the islets, where they either arrest or promote transition of dysplastic islets into islet carcinomas. Through combined TNFR1 signaling and IFN-gamma signaling, Tag-specific CD4+ T cells induce antiangiogenic chemokines and prevent alpha(v)beta(3) integrin expression, tumor angiogenesis, tumor cell proliferation, and multistage carcinogenesis, without destroying Tag-expressing islet cells. In the absence of either TNFR1 signaling or IFN-gamma signaling, the same T cells paradoxically promote angiogenesis and multistage carcinogenesis. Thus, tumor-specific T cells can directly survey multistage carcinogenesis through cytokine signaling. 相似文献
1000.
Schwenkert M Birkholz K Schwemmlein M Kellner C Kügler M Peipp M Nettelbeck DM Schuler-Thurner B Schaft N Dörrie J Ferrone S Kämpgen E Fey GH 《Melanoma research》2008,18(2):73-84
A recombinant immunotoxin was constructed by fusing a single chain fragment variable antibody fragment, specific for the melanoma-associated chondroitin sulfate proteoglycan (MCSP), to a truncated variant of Pseudomonas exotoxin A (ETA'), carrying a C-terminal KDEL-peptide for improved retrograde intracellular transport. The resulting immunotoxin MCSP-ETA' was periplasmatically expressed in Escherichia coli and purified under native conditions by affinity chromatography resulting in a yield of approximately 30 mug/l bacterial culture. This immunotoxin induced antigen-specific apoptosis in the cultured human melanoma-derived cell lines A2058 and A375M, and treatment with a single dose of the agent eliminated up to 80% of these cells within 72 h. The dose needed for half-maximum killing (EC50) was approximately 1 nmol/l for both cell lines. MCSP-ETA' also displayed cytotoxic activity against cultured primary melanoma cells from patients with advanced disease (pathologic stages IIIC and IV), with net cell death reaching up to 70% within 96 h after treatment with a single dose of 14 nmol/l. MCSP-ETA' induced cell death synergistically with cyclosporin A, both in established human melanoma cell lines and cultured primary melanoma cells. The distinctive antigen-restricted induction of apoptosis and the synergy with cyclosporin A justify further evaluation of this novel agent with regard to its potential application for the treatment of malignant melanoma. 相似文献